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Abstract:  
Human Embryonic stem cells (hESCs) represent a pluripotent cell population derived 
from the inner cell mass (ICM) of the blastocyst stage of the developing embryo. Ethical 
concerns have been raised regarding the derivation process, as the procedure ultimately results in 
the destruction of the embryos. Recently, alternative approach has been devised that 
encompasses reprogramming of terminally differentiated cells into an hESC-like state. This 
process relies on the over-expression of four pluripotency-associated factors, and successfully 
reprogrammed cells are termed induced pluripotent stem cells (iPSCs). These cells hold great 
promise for the use in future cell-based therapeutics such as evaluating drug induced toxicity and 
developing personalized medicines. However, the intricacies of the reprogramming mechanism 
are not fully understood, mostly due to the random nature of the expression of the four factors. In 
this study, I propose a series of experiments involving a novel molecular switch, known as 
Rheostat system, along with the doxycycline inducible system, that will regulate the expression 
of the four transcription factors in a precise temporal manner. Controlled expression of the 
transcription factors will help to elucidate underlying molecular mechanisms of the 
reprogramming process.  
Background and Introduction: 
Stem cells can be categorized into two major categories according to their potency of 
differentiation: adult stem cells and pluripotent stem cells.1 Adult stem cells, such as 
hematopoietic and mesenchymal stem cells, generally have limited potential for growth and 
differentiation. In contrast, pluripotent stem cells such as embryonic stem cells (ESCs) have the 
capacity to give rise to any type of cell in the body, and to grow indefinitely in the laboratory 
setting.1 Therefore, pluripotent stem cells offer greater potential to be used therapeutically than 
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adult stem cells.1,2 For example, ESCs provide indefinite resources for generating somatic cells 
that can be employed in cell-based regenerative therapies. This is of particular relevance for 
diseases such as Parkinson’s disease, leukemia and muscular dystrophy in which cell 
transplantation can functionally surrogate the tissue damages that are caused by environmental 
agents, mutations or injury.1,2 Unfortunately, ESC research is currently obstructed by two major 
issues. One is the ethical issue associated with the derivation of human ESCs from human 
fertilized eggs, and the other is the immunological incompatibility between ESC-derived donor 
organs or cells and the recipients because of differences in the histocompatibility factor.2 
The development of Induced Pluripotent Stem cells (iPSCs), pioneered by Takahashi and 
Yamanaka, have advanced stem cell research by circumventing these issues.3 Unlike the 
derivation of ESCs from ICM, iPSCs can be obtained by reprogramming readily accessible 
patient’s somatic cells with either sets of four transcription factors, Oct4, Sox2, cMyc, and Klf4 
or Oct4, Nanog, Sox2 and Lin28.3 These reprogrammed cells are in an ESC-like state that 
convey most of the therapeutic values that ESCs offer.3 Because iPSCs are derived from each 
individual, they eliminated histocompatibility issues that were previously associated with ESCs.4 
Therefore, iPSCs can be differentiated into certain tissues and be transplanted into patients with 
no potential risk of immune rejection.5 These tissues can also be used in in-vitro studies to 
elucidate patient-specific disease pathogenesis and discover methods yielding the best course of 
treatment.5	  
Use of iPSC technology is also useful in predicting the therapeutic benefit of certain 
medications. Not all medications have an equal effect in patients.6 Some patients receive a 
beneficial effect from medication while others do not and small subsets of patients exhibit 
undesirable side effects that pose serious consequences.5 Those side effects often occur in 
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cardiac, hepatic, and neural cells and they can be fatal.5 Unfortunately, those side effects are	  
often idiosyncratic and are discovered after patients have taken the medication.7 By using 
patient-specific iPSCs production followed by differentiation into cardiac, hepatic and neural 
cells, it is now possible to determine individualized patient responses to a certain medication 
prior to administration.7 By conducting several drug efficacy tests in those major tissues in-vitro, 
it is practicable to predict which medication would have the best therapeutic effect and have the 
least risk of adverse reaction on an individual basis.6,7 Screening of iPSCs may also lead to the 
discovery of genetic defects in the patients and can help find the most effective interaction of a 
drug with those defective genes to eliminate certain physiological effect on patients.8 Therefore, 
patients can receive personalized medication that will be most effective through the usage of 
iPSC technology. iPSC technology is certainly a key application that has many beneficial uses 
and is a key to amend the technical and ethical problems associated with ESC research.	  
Despite their great therapeutic promise, the value of iPSCs is hampered by the prolonged 
duration of more than 21 days for reprogramming and by a low success rate of less than 0.1 
percent.6 Also, increased mutational loads that have accumulated in somatic cells over the 
patient’s life span are found to be responsible for varying results of reprogramming process.7 
There have been intense studies to understand the underlying transcriptional and chromatin-
based mechanisms during reprogramming process.8 However, there are still many questions that 
are left unanswered. The answers to these questions will be crucial for improving the 
reprogramming efficiency and further advancing the therapeutic application of iPSCs. Therefore, 
I focused to study the temporal requirement of expression of each gene during the course of the 
reprogramming process by utilizing novel inducible molecular switch, Rheostat system, along 
with doxycycline system to expound the way to increase the efficiency in generating iPSCs. The 
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temporal tuning of factor expression permits to analyze at which time span a particular gene is 
most active. This, in turn, will provide information about a specific time period when cells need 
to be induced to express specific genes.  
 Preliminary Data: 
 Currently, our lab utilizes a doxycycline-dependent system to regulate the expression of 
four transcription factors (Figure 1). This system ensures simultaneous expression of the four 
genes. All transcription factors are induced three days after the transfection by the addition of 
doxycycline and the induction is ceased fifteen days later by the removal of doxycycline. This 
system may be more efficient in inducing gene expressions, but it does not reveal any specific 
information about how each transcription factor affects the reprogramming process and may be 
less efficient in generating iPSCs. Controlling gene expression by more than one gene switch is 
advantageous because each gene expression can be separately induced. Therefore, if each 
transcription factor is regulated by an independent molecular switch, the effects of each gene 
during the reprogramming process can be observed by the several induction and discharge of 
reprogramming genes during the of reprogramming process which would ultimately elucidate the 
temporal requirement of gene expression in various time periods.   
Rheostat System 
The Rheostat system is a novel ecdysone receptor (EcR)-based gene switch, which can be 
implicated in various molecular applications such as gene therapy, recombinant protein 
production, functional genomics, and regulation of transgenic gene expression.11,12 EcR is a 
member of the nuclear receptor superfamily that plays an important role in regulating 
development and reproduction in insects.11 In the case of insects and some plants, the application 
of an EcR-based gene switch could be limited by the presence of endogenous ecdysteroids that 
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could potentially activate the system.12 However, an EcR-based gene switch is attractive for 
mammalian application because both the receptor and ligand are foreign to mammalian cells.12 
Absence of endogenous ecdysteroid in mammalian cells lowers the potential to cross-activate the 
system, however, it was reported that exogenous steroid such as growth hormone present in 
media or endogenous steroid produced within the mammalian cells can also have some affinity 
to EcR and can activate transcriptional response.12 Therefore, the Rheostat system was developed 
in order to decrease receptor affinity to steroidal ligands but retain high affinity to a synthetic  
nonsteroidal ligand so that the expression can solely be controlled by the presence of synthetic 
ligand.12 The mutation of a critical alanine residue, A110, to proline in the ligand binding domain 
of EcR was introduced, leading to a selective disruption of both binding and transactivation with 
steroids but not with nonsteroidal ligand.12,13 A synthetic non-steroidal ligand, known as RSG-1, 
was found to have high affinity to this single point-mutant receptor and was shown to activate 
ecdysone responsive genes effectively.13 Furthermore, the target gene expression was revealed to 
be increased in ligand dose dependent manner and can repeatedly turned on and off by the 
addition and removal of ligand.12 Therefore, Rheostat system seems to be suitable gene switch 
machinery, which can be utilized in conjunction with the doxycycline-dependent system in 
studying temporal tuning of reprogramming genes.  
The Rheostat system is comprised of three components: Rheo Receptor (Rheo R), Rheo 
Activator (Rheo A), and Rheo Response Element (RRE). Rheo R, in concert with RSG-1 
heterodimerizes with Rheo A and moves across the nuclear membrane. The binding of the two 
proteins transactivates and binds to RRE to generate gene expression (Figure 2).13  In order to 
utilize this system in our fibroblasts, three components of Rheo system were cloned into two 
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lentiviral vector, FU-ΔGWMCS-T2A and FU-ΔeGFP-T2A-LUC. Concise overview of construct 
preparation is explained below. 
Materials and Methods: 
Cell Cuture 
The DNA plasmids in pNERB-R1 backbone containing gene segments of Rheo R and 
Rheo A were purchased from Milipore stably expressed in 293T cells (Figure 3). The 293T cells 
were cultured on 10cm-diameter culture plate in 1X DMEM medium, supplemented with 10% 
fetal bovine serum, 0.6% Geneticin 418 and 0.5% Doxycycline. Within 24-48 h, the cells 
achieved greater than 80% confluence, and were dissociated by 0.05% trypsin-EDTA and 
passaged onto three 10cm-diammeter-culture dishes to cultivate high yield. Cells were harvested 
at 80% confluency by dissociation with 0.05% trypsin-EDTA and were pelleted by five minutes 
of centrifugation at 1,000rpm. 
Extraction of genomic DNA 
The genomic DNA was extracted by lysing cell pellet with 3 ml of lysis buffer (50mM 
Tris-HCl in pH 8, 50 mM EDTA, 1% SDS and 10mM NaCl). Lysed cells were centrifuged at 
13,100 rpm for 10 minutes to remove cell debris. Fifteen µl of Proteinase K (NEB, Ipswich, MA) 
was added to the supernatant and was incubated for 18 hours at 37°C. Three ml of phenol was 
then added to the supernatant and was placed in the shaker for 12 hours. The supernatant was 
centrifuged at 13,100 rpm for 15 minutes at 4°C and the bottom phase of the supernatant was 
removed with a P1000 pipette.  Three ml of phenol were added to the residual supernatant and 
the procedure was repeated once again. Three ml of chloroform were added to the upper phase of 
the supernatant from the phenol extraction, and was placed on the shaker for 12 hours. The upper 
phase of the supernatant was discarded by P1000 pipette and 2X volume of ethanol and 0.1X 
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volume of sodium acetate were added to precipitate genomic DNA. Precipitated genomic DNA 
was diluted in 1M of Tris-EDTA buffer (pH 8) and was stored in 4°C. 
PCR 
Rheo R and Rheo A were amplified by polymerase chain reaction (PCR) using Biorad’s 
Icycler. Primers were designed to recognize each segments of Rheo R and Rheo A in the 
pNERB-R1 vector and the sequences of the primers are shown in Table 1 with their respective 
melting points. Two separate PCR were performed for Rheo R and Rheo A. For both reactions, 
PCR was prepared by adding 10 µM of its forward and reverse primers, 5 µl of 10X Buffer, 10 
mM of dNTPs and 1 µg of Taq polymerase to 1 µg of genomic DNA. PCR was carried out in 30 
cycles of 60, 60, and 90 seconds at 95°C, 58°C, and 68°C and an additional 10 minutes of 
extension period was provided at the end of the reaction at 72°C. For Rheo A, PCR was carried 
out in 30 cycles of 60, 60, and 90 seconds at 95°C, 60°C, and 68°C, and an additional 10 minutes 
of extension period was provided at the end of the reaction at 72°C as well.  
Electrophoresis 
The agarose gel was prepared by adding 400mg of SeaKem LE Agarose (Lonza, 
Rockland, ME) in 50ml of 1X TAE (Bio-Rad, Hercules, CA) and the addition of 5 µg of 
fluorescent dye, Ethidium Bromide (Bio-rad, Hercules, CA). The agarose was dissolved in TAE 
by heating up to boiling point, and was cooled down in 50°C water bath. The agarose was then 
poured into 8cm x 10cm gel box with the comb properly inserted. The 2X volume of 
bromophenol blue was added to the PCR products, and was loaded into the wells after the gel 
was solidified. The gel was transferred to electrophoresis machine containing a sufficient volume 
of 1X TAE running buffer to submerge the gel. Electrophoresis was performed at 100V until 
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bromophenol blue has run ¾ the length of the gel. The gel was then observed under Benchtop 
3UVTM Transilluminator.  
Gel Extraction 
All gel extraction was performed by using QIAquick gel extraction Kit (Qiagen, 
Valencia, CA), following the manufacturer’s instruction.  
TOPO Cloning and Transformation 
The PCR products were introduced into pCR2.1-TOPO vector using Invitrogen’s TOPO-
TA cloning kit (Figure 5, Invitrogen, www.invitrogen.com). The ligated TOPO vector were then 
transformed into TOP10 chemically competent E.coli cells using standard protocol and plated 
onto 10cm diameter LB plates supplemented with, 100µg of ampicillin, 50 µg of X-GAL and 
IPTG.  Ten colonies were picked including one light blue colony for negative control after 12 
hours of incubation at 37°C. Each colony was transferred into the glass tube in 5ml of LB broth, 
supplemented with 100µg of ampicillin and placed in the shaker for 12-14 hours at 37°C. All ten 
samples were centrifuged for 3 minutes at 13,100 rpm and were pelleted for genomic DNA 
extraction. 
DNA Extraction 
All DNA of the samples were extracted by using QIAprep Spin Miniprep kit (Qiagen, 
Valencia, CA). The procedure was executed following manufacturer’s instruction.  
Restriction Enzyme Digestion 
All restriction enzymes used in this experiment were purchased from BioLab, Inc. and 
was performed following manufacturer’s instruction. One µg of the samples was incubated for 
90~120 minutes at 37°C and were separated by electrophoresis.  
Ligation 
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All ligation of plasmids and vectors were carried out by using T4 DNA ligase (BioLab, 
Inc., 400,000U/ml). The ligation reactions were comprised of 1 µg of lentiviral vector, 1 µg of 
Rheo R or Rheo A that were diluted into 1:10, 1:100, and 1:500 ratios, 1µl of 10X Buffer for T4 
DNA Ligase with 10 mM ATP, and 1 µl of T4 DNA ligase. The ligation reactions were 
incubated at 16°C for 12-16 hours by using Programmable Thermal Controller (MJ Research, 
Inc. www.mj-research.com) and were transformed into HB101 competent cells. The RRE was 
also ligated into the vector following the same procedure.  
Transfection 
 293T cells were passaged 12 hours prior transfection to a 6-wells plate at a density of 
3x10^5 cells per well. Cells were transfected with each of the construct by using TransIT-2020 
transfection protocol (Mirus, Madison, WI).  Two and half µg of each construct were separately 
diluted in 250 µl of 1X Opti-MEM I Reduced-Serum Media (Gibco, www.invitrogen.com) in a 
sterile tube and 7.5 µl of TransIT-2020 Reagent was added. The mixtures were then vortexed to 
mix completely and were incubated at room temperature for 30 minutes.  After 30 minutes, 
mixtures were added drop-wise to different areas of the wells to complete transfection. Cells 
were induced with different concentration of RSG-1 (5nM, 50nM, 500nM and 1000nM) 12 
hours after the transfection and were harvested 36 hours after for luciferase assay. 
RSG-1 
 RSG-1 was purchased from MiliporeTM (Catalog number: 20-382) and was supplied in 
5mM in 100% DMSO. RSG-1 was diluted in cell media to concentrations of 5nM, 50nM, 
500nM and 1000nM and was stored at 4°C. Manufacturer reported that the ligand can be stored 
in cell media at 4°C for several weeks with no loss of activity and that media containing the 
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ligand can be added to cells in culture and incubated at 37°C for many days while still retaining 
full functionality.  
Luciferace Assay 
 Luciferase activity was measured by L-Max Molecular Devices 48 hours after the 
induction. The cells were scraped from the plates and their cell counts were calculated by using 
hemocytometer. Cells were pelleted by 5 minutes of centrifugation at 13,100 rpm and were lysed 
with 200 µl of 1X passive lysis buffer (Promega, Madison, WI). Cell debris was removed by 10 
minutes of centrifugation at 13,100 rpm and 8 µl of supernatant was mixed with 50 µl of 
Luciferase Assay Reagent right before the reading. All experiments were carried out in triplicate 
and the average values were computed in graph. All luciferase activity was normalized by their 
cell counts that were calculated prior harvesting.  
eGFP Activity 
 The transfected cells were observed under the fluorescent microscope, Olypus IX51, to 
detect eGFP activity prior to harvesting for luciferase assay.  
Results: 
Subcloning of Rheo R and Rheo A 
The DNA plasmids in pNERB-R1 backbone containing gene segments of Rheo R and 
Rheo A were purchased from Milipore stably expressed in 293T cells (Figure 3). Cells were 
cultured and harvested and their genomic DNA was extracted by several phenol and chloroform 
extractions. Rheo R and Rheo A were amplified by two separate PCR and the PCR products 
were separate by electrophoresis (Figure 4). The PCR products were excised from the gel and 
extracted by using Qiagen’s gel extraction kit. Purified PCR products were then introduced to 
PCR2.1-TOPO vector using standard protocol (Figure 5). The ligated TOPO vectors were 
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transformed into TOP10 chemically competent cells and cultured in LB plates as described 
above. The 10 colonies were picked including one light blue colony for negative control and 
were cultured in LB broth for 16 hours. The cells were centrifuged and their genomic DNA were 
extracted by using Qiagen’s miniprep kit. Three µg of each genomic DNA from 10 samples were 
digested with 20 units of EcoRI restriction enzyme (10,000U/ml) for 90 minutes at 37 °C and 
were separated by electrophoresis in 0.8% gel. The proper insertions of Rheo R and Rheo A into 
pCR2.1-TOPO vector are confirmed by observing 1000bp and 1500bp fragments excised from 
the vectors (Figure 6). All genomic DNA samples that showed proper insertions were sequenced 
in order to detect any mutation that may have occurred during PCR and transformation. Their 
sequences were compared to the parent Rheo R and Rheo A sequences obtained from Genebank 
and analyzed by using ApE software. For Rheo R, various mismatches and 17 bp insertion near 
the 3’ end were discovered in all 9 samples. The common mismatches were at A678, T838, and 
A1222 residues, which caused the mutation to threonine, glycine, and glycine respectively Also, 
a 17 bp insertion near the 3’ end generated a protein truncation by 10 amino acids. Since, all nine 
samples contained similar mutation patterns, it was deduced that the published sequence from 
Genebank was not reflecting the Rheo R sequence used by the manufacturer. The Rheo R sample 
that contained lowest number of mismatches was selected to clone into the lentiviral construct, 
FU-ΔGWMCS-T2A (Figure 7). For Rheo A, all samples carried at least one mismatch at 171bp 
region that caused the mutation of glycine to threonine. Since, this mutation was observed in all 
other samples, it was deduced that it was likely due to an error in the published sequence. The 
Rheo A sample that only contained one mismatch at 171bp region was selected to be cloned into 
FU-ΔGWRR-T2A (Figure 8).  
Lentivector Construction 
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 The lentiviral construct, FU-ΔGWMCS-T2A plasmid, was provided by Dr. Krueger. This 
plasmid contains human ubiquitous promoter (hUBC), multiple cloning site (MCS), and T2A 
peptide (Figure 9). T2A is one of the “self-cleaving” 2A peptides that enable dual expression of 
the gene from single promoter through a ribosomal skip mechanism. Therefore, Rheo R and 
Rheo A were cloned into our lentiviral construct separated by T2A peptide for bicistronic 
expression of Rheo R and Rheo A in regulation of single promoter, hUBC.  
Rheo R into FU-ΔGWMCS-T2A  
 Rheo R was excised by 20 units of NheI (10,000U/ml) and StuI (10,000U/ml) restriction 
enzymes from the 5 µg of pCR2.1-TOPO vector and was separated and purified by 
electrophoresis and Qiagen’s gel extraction kit (Figure 10B). Five µg of the lentiviral construct, 
FU-ΔGWMCS-T2A, was cut by 20 units of NheI (10,000U/ml) and HpaI (10,000U/ml) 
restriction enzymes and purified by gel extraction using Qiagen’s gel extraction kit (Figure 10A). 
These two constructs were then ligated by the T4 DNA ligase and were transformed into HB101 
competent cells. Cells were cultured and picked in the same condition as described before. Their 
genomic DNA were extracted using Qiagen’s miniprep kit. The resulting plasmid was designated 
as FU-ΔGWRR-T2A (Figure 11C) and proper insertion of Rheo R was confirmed by SmaI 
digestion (Figure 11D).  
Rheo A into FU-ΔGWRR-T2A  
 Both Rheo A and FU-ΔGWRR-T2A contain Sfi I restriction enzyme recognition site and 
were both excised and extracted by using Qiagen’s gel extraction kit (Figure 12). Two extracted 
plasmids were ligated by T4 DNA ligase and transformed into HB101 competent cells. Cells 
were grown and harvested and their genomic DNA was extracted by using Qiagen’s miniprep 
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kit. The resulting plasmid was designated as FU-ΔGWRR-T2A-RA (Figure 13C) and the proper 
insertion of Rheo A was confirmed by ScaI digestion (Figure 13D).  
Rheo Response Element 
 RRE was not provided from the manufacturer and it was constructed by hybridizing four 
oligonucleotides that were synthesized based on the sequence data obtained from Genebank. The 
schematic drawing of RRE oligonucleotides are shown in Figure 14A and the sequences of the 
four oligonucleotides are available in Table 2. The 5 µl of each of the four oligonucleotides 
(100µM) were combined along with 5 µl of 10X NEB 2 buffer and 25 µl of water to bring the 
final volume to 50 µl. These nucleotides were annealed by nucleic acid hybridization which was 
placed into the beaker containing 95°C water that was cooled down to room temperature over 
night. Annealed RRE was then cloned into FU-ΔGW-eGFP-T2A-LUC vector, which was 
provided from Dr. Gurevich in our lab. FU-ΔGW-eGFP-T2A-LUC vector was excised by PacI 
and BamHI digestion to remove hUBC from the vector and was replaced with RRE (Figure 14). 
RRE and digested FU-ΔGW-eGFP-T2A-LUC vector were transformed into HB101 competent 
cells. The cells were cultured and picked in the same condition as discussed earlier and their 
genomic DNA was extracted by using Qiagen’s miniprep. The confirmation of RRE insertion 
into FU-ΔGW-eGFP-T2A-LUC was verified by ScaI digestion and the resulting plasmid was 
designated as FU-ΔRRE-eGFP-T2A-LUC (Figure 15). The samples that were confirmed the 
proper insertion, were processed to be sequenced in order to verify accurate nucleic acid 
hybridization and transformation. No mismatch was found in all samples (Figure 16). 
Confirmation of Rheostat gene switch mechanism 
  293 T cells were transfected with both FU-ΔRRE-eGFP-T2A-LUC and FU-ΔGWRR-
T2A-RA vectors and were induced with different concentration of RSG-1 to confirm proper 
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transfection and integration of the two lentiviral constructs within the genome. The cells were 
observed under the fluorescent microscope to detect eGFP activity (Figure 17). The eGFP 
activity was shown to increased in ligand depended manner; the cells induced with higher 
concentration of ligand showed higher activity of eGFP activity. There was not any eGFP 
activity observed in the cells that were not transfected (NT). However, deem eGFP activity was 
also observed from the transfected cells that were not induced with RSG-1 (0nM). In order to 
quantify the gene expression activity of the Rheostat system, all cells were harvested to measure 
their luciferase activity. Luciferase data of all cells in different experiment conditions in triplicate 
are shown in Table 3. Luciferase assay showed the dose dependent increase in luciferase activity 
as well (Figure 18). Highest luciferase activity was observed from the cells induced with 
1000nM and the lowest from the cells induced with 5nM. Luciferase activity was also detected in 
the negative control sample as expected (0 nM). To further test this abnormal expression, another 
luciferase assay was performed to see how each of the constructs has an effect on abnormal 
expression. Cells were only transfected with either construct and were induced with 500nM of 
RSG-1 prior to harvesting for luciferase activity (Figure 19).  Luciferase activity was only 
detected in the cells that had RRE transfected. No luciferase activity was detected in the cells 
that were only transfected with FU-ΔGWRR-T2A-RA. This conferred that FU-ΔRRE-eGFP-
T2A-LUC itself can induce gene expression when integrated into 293T cells without FU-
ΔGWRR-T2A-RA. It also showed that Rheo R and Rheo A are functioning accurately, since the 
luciferase activity was increased in ligand-dependent manner as it was observed in previous 
experiment and the expression was halted when RRE was not present. It is not clear whether 
exogenous steroids in cell media activate certain nuclear receptors that share similar binding 
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domain as RRE to bind and initiate gene expression or RRE itself initiate expression without any 
regulatory control.  
 In order to elucidate whether other exogenous chemicals such as growth hormones 
present in FBS serum effects expression, cells were cultured in four different concentration of 
serum (10%, 7.5%, 5%, 2.5%) prior to and after the transfection with FU-ΔRRE-eGFP-T2A-
LUC . Cells were not induced with RSG-1 and their luciferase activity were measured 36 hours 
after the transfection (Figure 20). There was a slight reduction in luciferase activity from the 
cells grown in lower concentration of media but that reduction did not correlate with decrease in 
serum concentration.  The lowest luciferase activity was detected in cells grown in 2.5% serum 
concentration, and the highest in 10%. However, there was slightly higher expression of 
luciferase activity in cells grown in 5% than the ones from 7.5%. There was some variability in 
cell counts especially with the cells grown in lower serum concentration. Cell counts were about 
30% less in the cells in grown in 2.5% serum and more cells were detached from the plates when 
they were harvested for luciferase activity. Also, there was an inconsistency of luciferase data 
between the triplicated samples, which hinders the validity and accuracy of the data produced in 
this experiment. Therefore, this experiment can be performed again to ensure similar cell counts 
between different experimental conditions to produce more reliable luciferase activity data.  
Discussion: 
 The iPSC technology holds a great therapeutic advantage and provides a vast potential 
for developing personalized treatments for diseases and for drug screening. However, the use of 
iPSC is hampered by the unknown mechanism of prolonged duration of reprogramming and a 
low success rate of less than 0.1%. The intricacies of the reprogramming mechanism are not 
fully understood, mostly due to the random nature of the expression of the reprogramming genes. 
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Also, most of the studies have used single inducible system to express all genes simultaneously, 
which has made it more difficult to observe the effect of each reprogramming genes during the 
reprogramming process. Therefore, the EcR based molecular switch, Rheostat system was 
utilized in conjunction with doxycycline-dependent molecular switch to explicate the effects of 
each reprogramming gene during the reprogramming process. Components of Rheostat system 
were cloned into two lentiviral vectors through subsequent steps of restriction enzyme 
digestions, ligations, and cloning, and were delivered into 293T cells. Rheostat system’s 
inducibility was tested with varying concentration of its ligand, RSG-1. Induced cells were 
observed under the fluorescent microscope to detect eGFP activity and were harvested to 
compare luciferase activity. The result showed that the Rheostat system can express the gene 
expression in ligand dose-dependent manner. However, gene expression was also detected in 
non-induced sample, which conferred that Rheostat system can be activated by other 
mechanisms. There are two possibilities in which Rheostat system can be activated without its 
ligand. One is that there are other steroidal ligands that have some affinity to Rheo R that bind 
and activate the system. The other is that RRE may have similar binding sites with other 
activated nuclear receptors, which can activate the system without its ligand RSG-1 and its 
receptors. Following experiment revealed that the abnormal activation of the system was 
depended on RRE as RRE itself generated gene expression in absence of its receptor, Rheo R 
and Rheo A. Rheo R and Rheo A were found to have no role in expressing random gene 
expression since there was no activation of the system when RRE was absence. Rheo R was 
binding RSG-1 and heterodimerized with Rheo A correctly and moved across the nuclear 
membrane to bound RRE. However, the RRE was absence and the gene expression was not 
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initiated. Therefore, it was deduced that RRE was sensitive to other activated nuclear receptors 
and has initiated the gene response.  
 The third experiment was performed to confirm RRE’s sensitivity to other nuclear 
receptor that can be activated by exogenous chemicals such as growth hormones in FBS serum. 
The result showed that RRE has some responsiveness to serum concentrations, as its expression 
was lower in the cells grown in lower serum concentration and higher in cells grown in higher 
serum concentration. However, this result was not reliable since the cells grown in 5% serum 
showed higher expression than the cells grown in 7.5%. This may be due to the serum 
concentration directly affecting cell growth. When the cells were harvested for luciferase assay, 
cell numbers were tended to be lower in the cells that were cultured in lower concentration of 
serum. This indicated that the low serum concentration has affected the growth of the cells, 
which may have further interrupted the transfection and integration efficiency of the construct 
into the DNA. Therefore, luciferase activity may not represent true RRE sensitivity to the serum 
concentration. In order to illustrate whether decreased in cellular growth or decreased in serum 
concentration led to lowering of the luciferase activity, experiment can be performed to 
demonstrate transfection efficiency of the vector, FU-ΔRRE-eGFP-T2A-LUC of all cells while 
maintaining good cellular environment for growth. The transfection efficiency then can be used 
to normalize luciferase data so that the different cell numbers among different experimental 
conditions would not skew the luciferase activity. This experiment would exemplify that 
luciferase activity can be equally compared without the concern of the cell growth among other 
samples and would show true responsiveness of RRE to serum concentration. The data obtained 
from this experiment can be crucial in determining RRE sensitivity to steroid and may assist in 
finding the cause of the abnormal RRE expression without an induction.   
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 It is unclear whether the manufacturer of Rheostat system utilizes different RRE 
sequences that were obtained from the Genebank or have incorporated co-regulatory genes to 
regulate the sensitivity of RRE to other nuclear receptor. Therefore, if there is a co-regulatory 
genes that assist in decreasing the sensitivity of RRE, new oligonucleotides can be synthesized to 
have such co-regulatory genes incorporated into the upstream of the binding sites of RRE. This 
new RRE then can be incorporated into FU-ΔGW-eGFP-T2A-LUC after excising hUBC by PacI 
and BamHI restriction enzyme digestion, and be transfected to 293T cells to confirm tight 
control of the gene expression. When the sensitivity of RRE to other nuclear receptor is 
completely eliminated, the Rheostat system can be incorporated into our fibroblast cell lines 
along with the doxycycline system to study temporal requirements of certain gene expression 
during the reprogramming process.  
Future Research Plan: Controlled Expression of Reprogramming Factors for Investigation 
of iPSC Mechanism. 
The combination of Rheostat and doxycycline inducible system offers an advantage in 
regulation of expression of transcription factors by two independent mechanisms. This provides 
many possible ways to investigate how each gene expression can affect reprogramming process 
over time. First, the affect of two factors that are found to be most essential during 
reprogramming process, Oct4 and Sox2 can be investigated.6 Oct4 plasmid will be cloned into 
FU-ΔRRE-T2A-Luc and be regulated by RSG-1. Sox2 plasmid will be cloned into our 
docycycline-dependent vector and will be regulated by doxycycline. The other two factors, cMyc 
and Klf4, will be cloned into the vector that is designed to produce expression constitutively. The 
experiments will be designed in a specific way to observe the reprogramming efficiency by 
expressing each gene in varying time period. For example, an equal number of fibroblast cells 
	   21	  
will be cultured in each well of 6-well plate and have all genes expressed. The first well, 
designated as Day 1, will have the expression of Sox2 turned off by stopping the addition of 
doxycycline into the well. Five days later, the expression of Sox2 in the second well will be 
halted. Following these procedures, the expression of Sox2 in each well will be halted in 5 day 
intervals. The cells will be observed under the microscope during this 25 days time-controlled 
experiment to detect the appearance of bona fide, the iPSC colonies. The number of iPSC 
colonies will be counted in each well and the results will be compared with our lab’s previous 
reprogramming data to estimate the reprogramming efficiency. The same experiment can be 
utilized by halting the expression of Oct4 in 5 day intervals. This experiment data can be 
compared with the one from Sox2 dependent experiment and our lab’s previous reprogramming 
data to assess the efficiency. If halting the expression of either gene does not affect the 
efficiency, the experiment can be employed in an opposite way; instead of halting the expression, 
expression can be induced in 5 day intervals and the results will be compared with previous data. 
In a parallel iteration, Oct4 and Sox2 will be expressed constitutively and Klf4 and cMyc will be 
placed under inducible control of expression and the experiment repeated as described above. 
Therefore, by having two molecular systems regulating the expression of the four genes, they 
permit many possible ways to study temporal requirement of reprogramming process by 
regulating each gene expression in varying time period. These experiments will allow 
observation as to which gene expression is most necessary during the course of the 
reprogramming process. Thus, it will ultimately facilitate the finding of optimal reprogramming 
condition, which can increase the efficiency and success rates of reprogramming fibroblast into 
iPSCs.  
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Figures and Tables: 	  	  	  	  	  	  	  
	  
Figure	  1.	  Diagram	  of	  doxycycline	  dependent	  induction	  of	  transcription	  factors	  used	  in	  generating	  iPSCs.	  Fibroblasts	  are	  transduced	  with	  four	  reprogramming	  genes	  and	  the	  expression	  is	  induced	  by	  the	  addition	  of	  doxycyline	  at	  day	  3.	  Induction	  ceases	  at	  day	  18	  by	  removing	  doxycycline.	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  
Figure	  2.	  Diagram	  of	  inducible	  mechanism	  of	  Rheostat	  system.	  When	  RSG-­‐1	  binds	  Rheo	  R,	  Rheo	  R	  heterodimerizes	  with	  Rheo	  A	  and	  moves	  across	  the	  nuclear	  membrane.	  The	  Rheo	  R	  and	  Rheo	  A	  complex	  then	  binds	  to	  RRE	  to	  generate	  gene	  expression.	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Figure	  3. Schematic drawing of the DNA plasmid in pNERB-R1 backbone, containing gene 
segments of Rheo R and Rheo A. The position of Rheo R and Rheo A is indicated in yellow and 
grey respectively. Gene segments of Rheo R and Rheo A are about 1,500 bp and 1,000bp long 
respectively. 	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Figure 4. (A). PCR of 1 µg of pNERB-R1 vector using Rheo R specific forward and reverse 
primers. Sequences of Rheo R specific primers are shown in Table 1 with their respective melting 
points.  Arrow indicates successful amplification of Rheo R. PCR Condition: 30 cycles of 60, 60 
and 90 seconds at 95°C, 58°C and 68°C respectively. 10 mins of extension period at the end of 
the reaction at 72°C.(B) PCR of 1 µg of pNERB-R1 vector using Rheo A specific forward and 
reverse primers. Sequences of Rheo A specific primers are shown in Table 1 with their respective 
melting points. Arrow indicates successful amplification of Rheo A. PCR condition: 30 cycles of 
60, 60 and 90 seconds at 95°C, 58°C and 68°C respectively. 10 mins of extension period at the 
end of the reaction at 72°C. 
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Figure	  5.	  	  Sequences	  and	  positions	  of	  the	  restriction	  enzyme	  recognition	  sites	  in	  LacZα	  fragment	  of	  pCR2.1-­‐TOPO	  vector.	  Insertion	  site	  for	  PCR	  product	  is	  highlighted	  in	  black.	  	  	  	   	  	  	  	  	  	  	  
Figure	  6.	  (A)	  EcoRI	  digestion	  of	  PCR2.1-­‐TOPO	  vector	  containing	  Rheo	  R.	  Digested	  vectors	  from	  10	  colonies	  were	  separated	  by	  electrophoresis	  in	  0.8%	  agarose	  gel.	  Proper	  insertion	  of	  Rheo	  R	  is	  confirmed	  in	  all	  nine	  samples	  (R1-­‐R9)	  by	  observing	  1000	  bp	  fragments	  excised	  from	  the	  vector.	  C	  indicates	  the	  genomic	  DNA	  attained	  from	  light	  blue	  colony	  for	  negative	  control.	  As	  expected,	  the	  digestion	  of	  the	  vector	  was	  not	  observed.	  (B)	  EcoRI	  digestion	  of	  PCR2.1-­‐TOPO	  vector	  containing	  Rheo	  A.	  Digested	  vectors	  from	  10	  colonies	  were	  separated	  by	  electrophoresis	  in	  0.8%	  agarose	  gel.	  Confirmation	  of	  proper	  insertion	  of	  Rheo	  A	  is	  confirmed	  in	  sample	  A1,	  A3,	  A5,	  A6	  and	  A9	  by	  observing	  1500bp	  fragments	  excised	  from	  the	  vector.	  C	  indicates	  negative	  control	  and	  the	  digestion	  was	  not	  observed	  .	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RheoReceptor_CDS1209-2675.ape from 1 to 1510 
Alignment to 
RheoR9.ape from 53 to 1580 
Matches(|):1507  
Mismatches(#):3  
Gaps( ):18  
Unattempted(.):0  
                *         *         *         *         *         *         *         *         *         * 
     1 ggctagcgatgccaccATGAAGCTACTGTCTTCTATCGAACAAGCATGCGATATTTGCCGACTTAAAAAGCTCAAGTGCTCCAAAGAAAAACCGAAGTGC 100    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
    53 GGCTAGCGATGCCACCATGAAGCTACTGTCTTCTATCGAACAAGCATGCGATATTTGCCGACTTAAAAAGCTCAAGTGCTCCAAAGAAAAACCGAAGTGC 152    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   101 GCCAAGTGTCTGAAGAACAACTGGGAGTGTCGCTACTCTCCCAAAACCAAAAGGTCTCCGCTGACTAGGGCACATCTGACAGAAGTGGAATCAAGGCTAG 200    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   153 GCCAAGTGTCTGAAGAACAACTGGGAGTGTCGCTACTCTCCCAAAACCAAAAGGTCTCCGCTGACTAGGGCACATCTGACAGAAGTGGAATCAAGGCTAG 252    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   201 AAAGACTGGAACAGCTATTTCTACTGATTTTTCCTCGAGAAGACCTTGACATGATTTTGAAAATGGATTCTTTACAGGATATAAAAGCATTGTTAACAGG 300    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   253 AAAGACTGGAACAGCTATTTCTACTGATTTTTCCTCGAGAAGACCTTGACATGATTTTGAAAATGGATTCTTTACAGGATATAAAAGCATTGTTAACAGG 352    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   301 ATTATTTGTACAAGATAATGTGAATAAAGATGCCGTCACAGATAGATTGGCTTCAGTGGAGACTGATATGCCTCTAACATTGAGACAGCATAGAATAAGT 400    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   353 ATTATTTGTACAAGATAATGTGAATAAAGATGCCGTCACAGATAGATTGGCTTCAGTGGAGACTGATATGCCTCTAACATTGAGACAGCATAGAATAAGT 452    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   401 GCGACATCATCATCGGAAGAGAGTAGTAACAAAGGTCAAAGACAGTTGACTGTATCGCCGGAATTCCCGGGGATCCGGCCTGAGTGCGTAGTACCCGAGA 500    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   453 GCGACATCATCATCGGAAGAGAGTAGTAACAAAGGTCAAAGACAGTTGACTGTATCGCCGGAATTCCCGGGGATCCGGCCTGAGTGCGTAGTACCCGAGA 552    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   501 CTCAGTGCGCCATGAAGCGGAAAGAGAAGAAAGCACAGAAGGAGAAGGACAAACTGCCTGTCAGCACGACGACGGTGGACGACCACATGCCGCCCATTAT 600    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   553 CTCAGTGCGCCATGAAGCGGAAAGAGAAGAAAGCACAGAAGGAGAAGGACAAACTGCCTGTCAGCACGACGACGGTGGACGACCACATGCCGCCCATTAT 652    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   601 GCAGTGTGAACCTCCACCTCCTGAAGCAGCAAGGATTCACGAAGTGGTCCCAAGGTTTCTCTCCGACAAGCTGTTGGAGACAAACCGGCAGAAAAACATC 700    
       |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||#||||||||||||||||||||||        
   653 GCAGTGTGAACCTCCACCTCCTGAAGCAGCAAGGATTCACGAAGTGGTCCCAAGGTTTCTCTCCGACAAGCTGTTGGTGACAAACCGGCAGAAAAACATC 752    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   701 CCCCAGTTGACAGCCAACCAGCAGTTCCTTATCGCCAGGCTCATCTGGTACCAGGACGGGTACGAGCAGCCTTCTGATGAAGATTTGAAGAGGATTACGC 800    
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   753 CCCCAGTTGACAGCCAACCAGCAGTTCCTTATCGCCAGGCTCATCTGGTACCAGGACGGGTACGAGCAGCCTTCTGATGAAGATTTGAAGAGGATTACGC 852    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   801 AGACGTGGCAGCAAGCGGACGATGAAAACGAAGAGTCTGACACTCCCTTCCGCCAGATCACAGAGATGACTATCCTCACGGTCCAACTTATCGTGGAGTT 900    
       |||||||||||||||||||||||||||||||||||||#||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   853 AGACGTGGCAGCAAGCGGACGATGAAAACGAAGAGTCGGACACTCCCTTCCGCCAGATCACAGAGATGACTATCCTCACGGTCCAACTTATCGTGGAGTT 952    
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
   901 CGCGAAGGGATTGCCAGGGTTCGCCAAGATCTCGCAGCCTGATCAAATTACGCTGCTTAAGGCTTGCTCAAGTGAGGTAATGATGCTCCGAGTCGCGCGA 1000   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   953 CGCGAAGGGATTGCCAGGGTTCGCCAAGATCTCGCAGCCTGATCAAATTACGCTGCTTAAGGCTTGCTCAAGTGAGGTAATGATGCTCCGAGTCGCGCGA 1052   
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
  1001 CGATACGATGCGGCCTCAGACAGTATTCTGTTCGCGAACAACCAAGCGTACACTCGCGACAACTACCGCAAGGCTGGCATGGCCGAGGTCATCGAGGATC 1100   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
  1053 CGATACGATGCGGCCTCAGACAGTATTCTGTTCGCGAACAACCAAGCGTACACTCGCGACAACTACCGCAAGGCTGGCATGGCCGAGGTCATCGAGGATC 1152   
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
  1101 TACTGCACTTCTGCCGGTGCATGTACTCTATGGCGTTGGACAACATCCATTACGCGCTGCTCACGGCTGTCGTCATCTTTTCTGACCGGCCAGGGTTGGA 1200   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
  1153 TACTGCACTTCTGCCGGTGCATGTACTCTATGGCGTTGGACAACATCCATTACGCGCTGCTCACGGCTGTCGTCATCTTTTCTGACCGGCCAGGGTTGGA 1252   
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
  1201 GCAGCCGCAACTGGTGGAAGAAATCCAGCGGTACTACCTGAATACGCTCCGCATCTATATCCTGAACCAGCTGAGCGGGTCGGCGCGTTCGTCCGTCATA 1300   
       |||||||||||||||||||||#||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
  1253 GCAGCCGCAACTGGTGGAAGAGATCCAGCGGTACTACCTGAATACGCTCCGCATCTATATCCTGAACCAGCTGAGCGGGTCGGCGCGTTCGTCCGTCATA 1352   
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *         *         * 
  1301 TACGGCAAGATCCTCTCAATCCTCTCTGAGCTACGCACGCTCGGCATGCAAAACTCCAACATGTGCATCTCCCTCAAGCTCAAGAACAGAAAGCTGCCGC 1400   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
  1353 TACGGCAAGATCCTCTCAATCCTCTCTGAGCTACGCACGCTCGGCATGCAAAACTCCAACATGTGCATCTCCCTCAAGCTCAAGAACAGAAAGCTGCCGC 1452   
              *         *         *         *         *         *         *         *         *         *   
                *         *         *         *         *         *         *         *                     
  1401 CTTTCCTCGAGGAGATCTGGGATGTGGCGGACATGTCGCACACCCAACCGCCGCCTATCCTCGAGTCCCCCACGAATCTCTA------------------ 1482   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||                          
  1453 CTTTCCTCGAGGAGATCTGGGATGTGGCGGACATGTCGCACACCCAACCGCCGCCTATCCTCGAGTCCCCCACGAATCTCTAGGCGGCCGCCTTTCGATC 1552   
              *         *         *         *         *         *         *         *         *         *   
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              *         *         * 
  1483 CCCCGGGCTGCAGGGAGATGGGGGAGGC 1510   
       ||||||||||||||||||||||||||||        
  1553 CCCCGGGCTGCAGGGAGATGGGGGAGGC 1580   
              *         *         * 
Figure	  7.	  The	  sequence	  alignment	  of	  Rheo	  R	  that	  was	  cloned	  into	  lentiviral	  construct,	  FU-
ΔGWMCS-T2A with	  the	  published	  sequence	  data	  obtained	  from	  Genebank. The mismatches 
and a 17bp insertion are highlighted in red. 
Figure	  8.	  The	  sequence	  alignment	  of	  Rheo	  A	  with	  the	  published	  sequence	  data	  obtained	  from	  Genebank.	  The	  Rheo	  A	  that	  was	  cloned	  into	  the	  lentiviral	  construct,	  FU-ΔGWRR-T2A, 
contained one mutation at 171bp region, which caused the single point mutation substituting 
threonine for glycine. 	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Figure	  9.	  Schematic	  drawing	  of	  the	  lentivirus	  transfer	  vector,	  FU-­‐ΔGWMCS-­‐T2A,	  indicating	  the	  position	  of	  the	  hUBC,	  T2A	  peptides,	  and	  respective	  restriction	  enzyme	  recognition	  sites	  that	  were	  utilized	  to	  clone	  Rheo	  R	  and	  Rheo	  A.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  10.	  (A)	  NheI	  and	  Hpa	  I	  digestion	  of	  FU-­‐ΔGWMCS-­‐T2A	  vector	  in	  0.8%	  agarose	  gel.	  Digested	  vector	  was	  divided	  and	  loaded	  into	  four	  consecutive	  wells.	  Excised	  fragments	  were	  18bp	  and	  were	  too	  small	  to	  be	  shown	  on	  the	  gel.	  	  All	  bands	  were	  excised	  and	  purified	  by	  gel	  extraction.	  (B)	  NheI	  and	  StuI	  digestion	  of	  TOPO	  vector	  containing	  Rheo	  R	  in	  0.8%	  agarose	  gel.	  The	  arrow	  shows	  successful	  excision	  of	  Rheo	  R	  from	  the	  vector.	  Two	  bands	  were	  excised	  and	  were	  purified	  using	  gel	  extraction.	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Figure	  11.	  (A)	  Schematic	  drawing	  of	  FU-ΔGWRR-T2A indicating	  the	  position	  of	  Rheo	  R	  and	  SmaI	  restriction	  enzyme	  recognition	  sites.	  (B)	  The	  map	  of	  Smal	  digestion	  of	  FU-
ΔGWRR-T2A .	  Excised	  fragments	  are	  7017,	  2514,	  1018,	  and	  195	  bp.	  (C)	  Schematic	  drawing	  of	  the	  vector,	  FU-ΔGWRR-T2A,	  after	  the	  insertion	  of	  Rheo	  R.	  (D)	  SmaI	  digestion	  of	  FU-
ΔGWRR-T2A after	  its	  genomic	  DNA	  extraction	  from	  HB101.	  Digested	  vector	  was	  separated	  by	  electrophoresis	  in	  0.8%	  agarose	  gel.	  Digested	  vector	  was	  divided	  and	  loaded	  into	  three	  consecutive	  wells	  (1~3).	  V	  is	  the	  undigested	  vector	  for	  the	  positive	  control	  and	  C	  is	  the	  unligated	  HB101	  vector.	  Proper	  insertion	  of	  Rheo	  R	  into	  FU-ΔGWMCS-T2A vector	  is	  confirmed	  by	  excision	  of	  expected	  fragments	  of	  7000,	  2500bp,	  and	  1000bp	  from	  the	  vector.	  200bp	  fragments	  can	  also	  be	  observed	  at	  longer	  UV	  exposure	  times.	  	  	  	  	  	  	  
A	  
	  B	  
D	  
Mon Apr 16, 2012 10:10 EDT
Fu-∆GwRR-T2A .ape
Size  site1   site2   Mass %
7017 SmaI 8005 SmaI 4277 65
2514 SmaI 5295 SmaI 7809 23
1018 SmaI 4277 SmaI 5295 9
196 SmaI 7809 SmaI 8005 2
4277 SmaI
5295 SmaI
7809 SmaI8005 SmaI
FU-ΔGWRR-T2A 	  C	  
4277 SmaI (4)
Rheo receptor 3828...5321
5295 SmaI (4)
T2A peptide 5325...5372
8005 SmaI (4)
7809 SmaI (4)
T2A peptide 5373...5378
Fu-∆GwRR-T2A 
10745 bp
hUBc 2602...3795
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Figure	  12.	  (A)	  Confirmation	  of	  Sfi	  I	  digest	  of	  Rheo	  A	  in	  pCR2.1-­‐TOPO	  vector.	  Digested	  vector	  was	  load	  into	  two	  wells	  and	  was	  separated	  by	  electrophoresis	  in	  0.8%	  agarose	  gel.	  	  The	  1000bp	  fragment	  confirmed	  the	  excision	  of	  Rheo	  A	  from	  the	  vector.	  1000bp	  fragments	  were	  excised	  from	  the	  gel	  and	  purified	  by	  gel	  extraction.	  	  (B)	  Confirmation	  of	  Sfi	  I	  digest	  of	  
FU-ΔGWRR-T2A.	  Digested	  vector	  was	  loaded	  into	  five	  consecutive	  wells	  and	  were	  separated	  by	  electrophoresis	  in	  0.8%	  agarose	  gel.	  FU-ΔGWRR-T2A only	  has	  two	  Sfi	  I	  site	  in	  close	  proximity	  and	  digestion	  of	  Sfi	  I	  enzyme	  linearized	  the	  construct.	  All	  bands	  were	  excised	  and	  purified	  by	  the	  gel	  extraction.	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Figure	  13.	  (A)	  Schematic	  drawing	  of	  FU-­‐ΔGWRR-­‐T2A-­‐RA	  showing	  the	  position	  of	  Rheo	  R,	  Rheo	  A	  and	  Sfi	  I	  restriction	  enzyme	  recognition	  sites.	  (B)	  Map	  of	  Sfi	  I	  digestion	  of	  FU-­‐ΔGWRR-­‐T2A-­‐RA	  indicating	  excised	  fragment	  of	  974bp.	  (C)	  Sfi	  I	  digest	  of	  FU-­‐ΔGWRR-­‐T2A-­‐RA	  after	  its	  genomic	  DNA	  extraction	  from	  HB101	  by	  mini	  prep.	  Digested	  vector	  was	  loaded	  into	  three	  consecutive	  wells	  designated	  as	  S1,	  S2	  and	  S3	  and	  were	  separated	  by	  electrophoresis	  in	  0.8%	  agarose	  gel.	  Proper	  insertion	  of	  Rheo	  A	  into	  FU-­‐ΔGWRR-­‐T2A	  vector	  was	  confirmed	  by	  excision	  of	  ~1000bp	  diagnostic	  bands	  indicated	  with	  arrow.	  (D)	  Schematic	  drawing	  of	  the	  vector,	  FU-­‐ΔGWRR-­‐T2A-­‐RA,	  indicating	  the	  insertion	  of	  Rheo	  A	  into	  FU-­‐ΔGWRR-­‐T2A.	  	  	  	  	  	  	  	  	  	  
hUBc 2602...3795
Rheo receptor 3828...5321
Fu-∆GwRR-T2A-
RA
11707 bp
T2A peptide 5376...5381
T2A peptide 5328...5375
Rheo Activator 5382...6346 5376 SfiI (2)
6350 SfiI (2)
Mon Apr 16, 2012 10:16 EDT
Fu-∆GwRR-T2A-RA.ape
Size  site1   site2   Mass %
10733 SfiI 6350 SfiI 5376 92
974 SfiI 5376 SfiI 6350 8
5376 SfiI
6350 SfiI
A	  
B	  
D	  
C	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Figure	  14.	  (A)	  Schematic	  drawing	  of	  RRE	  oligonucleotide	  hybridized	  to	  form	  RRE.	  Four	  different	  oligonucleotides,	  T1,	  T2,	  B1,	  and	  B2	  were	  synthesized	  based	  on	  the	  gene	  sequences	  provided	  from	  Genebank.	  (B)	  PacI	  and	  BamHI	  digestion	  of	  FU-ΔGW-eGFP-T2A-
LUC on 0.8% agarose gel. Digested vector was divided in half and was loaded onto two 
consecutive wells, designated as E1 and E2. 1300 base pair fragments were excised from the 
vector, which indicated the excision of hUBC. Vectors were excised from the gel and purified by 
gel extraction. Purified products were then ligated with RRE and were transformed into HB101 
cells.	  
 
 
 
 
 
 
 
 
 
 
T1	   T2	  
B2	   B1	  
A	   B	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Figure 15. (A) Schematic drawing of FU-ΔRRE-eGFP-T2A-LUC vector and its ScaI restriction 
enzyme recognition sites. (B) Map of ScaI digestion of FU-ΔRRE-eGFP-T2A-LUC vector. 
Expected size of excised fragments are 6405, 3047, 1047 and 19 base pairs. (C) Schematic 
drawing of the vector, FU-ΔRRE-eGFP-T2A-LUC, indicating the insertion of RRE into FU-
ΔGW-eGFP-T2A-LUC. (D) ScaI digestion of FU-ΔGW-eGFP-T2A-LUC after its genomic DNA 
extraction from HB101 by mini prep. Digested vector was divided and loaded into two wells 
designated as E1 and E2. Proper insertion of RRE into FU-ΔGW-eGFP-T2A-LUC was 
confirmed by observing excised fragments of about 1000 and 3000 bp. 
 
 
 
 
 
Rheo Response Element 2594...2747
Kozak 2754...2759
EGFP 2760...3476
T2A peptide 3483...3530
T->C (silent) 3842...3842
luc2 (+MGL) 3537...5198
Fu-∆RRE-eGFP-
T2A-Luc 
10556 bp
2624 ScaI (6)
2605 ScaI (6)
2643 ScaI (6)
2662 ScaI (6)
3709 ScaI (6)
10114 ScaI (6)
Mon Apr 16, 2012 13:30 EDT
Fu-∆RRE-eGFP-T2A-Luc .ape
Size  site1   site2   Mass %
6405 ScaI 3709 ScaI 10114 61
3047 ScaI 10114 ScaI 2605 29
1047 ScaI 2662 ScaI 3709 10
19 ScaI 2605 ScaI 2624 0
19 ScaI 2624 ScaI 2643 0
19 ScaI 2643 ScaI 2662 0
2605 ScaI244362
3709 ScaI
10114 ScaI
A	   D	  
	  B	  
C	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Figure 16. The sequences of RRE aligned with the published sequence data obtained from 
Genebank. No mismatches were found, confirming accurate nucleic acid hybridization and 
transformation into FU-ΔGW-eGFP-T2A-LUC construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. The eGFP activity observed by fluorescent microscope at 20X after 48 and 72 hours 
of the induction and transfection respectively. The eGFP activity was greater in cells induced 
with higher dose of the ligand, RSG-1. No eGFP activity was observed from the cells that was 
not transfected (NT). Deem eGFP activity was observed from the transfected cells that were not 
induced with the RSG-1 (0 nM). 
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Figure 19. The Effect of each construct in luciferase activity. 293T cells were only transfected 
with either FU-ΔRRE-eGFP-T2A-LUC or FU-­‐ΔGwRR-­‐T2A-­‐RA	  construct and induced with 
500nM of RSG-1. Luciferase activity was only detected in sample that had RRE transfected. No 
luciferase activities were detected in other samples, which indicated that RRE can generate gene 
expression without its receptor mechanism. 
Figure 18. RSG-1 Responsivenss in 293T cells. 293T cells were co-transfected with both FU-
ΔRRE-eGFP-T2A-LUC and FU-­‐ΔGwRR-­‐T2A-­‐RA	  constructs 12 hours prior to induction of four 
different ligand concentrations. Forty-eight hours after induction, cells were harvested for firefly 
luciferase assay.  No luciferase activity was detected in negative control (NT) which both of the 
constructs were not transfected. The average value for each triplicate experiment is shown in the 
graph. The results show that luciferase activity increase in ligand dependent manner, but its 
activity was also detected in the non-induced sample (0 nM). 
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Figure 20. RRE Responsiveness to FBS in media. Cells were cultured in four different FBS 
concentration and were transfected only with FU-ΔRRE-eGFP-T2A-LUC. RSG-1 was not added 
in order to expound RRE sensitivity to other endogenous nuclear receptor that may have been 
activated by growth hormone or other chemical compound present in FBS. Lower luciferase 
activity was detected in cells grown in lower concentration of FBS. 
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Tables: 
 
Rheo R-Forward 5’-ggctagcgatgccaccatgaagctactgtcttctatcgaa-3’ 60°C 
Rheo R-Reverse 5’-ctttaaggcctgcctcccccatctccctg-3’ 55°C 
Rheo A-Forward  5’-cgggccctatgggccctaaaaagaagcg-3 47°C 
Rheo A-Reverse 5’-gaggccgcatgggcctcagaaggtgattcaagcat-3’ 57°C 
Table	  1.	  Primer	  sequences	  used	  to	  amplify	  Rheo	  R	  and	  Rheo	  A	  from	  pNERB-­‐R1	  vector	  and	  their	  melting	  temperature	  	  
RRE  5’-TTAATTAAcggagtactgtcctccgagcggagtactgtcctccgagcggagtactgtcctccgagcggagtactgtcctccgagcggag 
ttctgtcctccgagcggagactctagagggtatataatgggggccgtcagctactaccaGGATCC-3’ 
RRE T1 5’-TAAcggagtactgtcctccgagcggagtactgtcctccgagcggagtactgtcctccgagcggagtactgtcctccgagcggagttctgtcct 
ccga-3’ 
RRE T2 5’-gcggagactctagagggtatataatgggggccgtcagctactaccaG-3’ 
RRE B1 5’-GATCCtggtagtagctgacggcccccattatataccctctagagtctccgctcggaggacagaactccgctcggaggacag 
tactccgctcggagga-3’ 
RRE B2 5’-cagtactccgctcggaggacagtactccgctcggaggacagtactccgTTAAT-3’ 
Table 2. Sequences of RRE and its four oligonucleotide. Sequence of RRE was obtained from 
Genebank and its oligonucleotides were synthesized (Integrated DNA Technologies, 
www.idtdna.com). Four oligos were annealed by nucleic acid hybridization.  
 
 #1 #2 #3 Average 
NT 0 0 0 0 
0 nM 96.275 89.785 88.677 91.579 
5nM 149.375 155.065 155.29 153.093 
50nM 243.336 245.931 250.872 246.713 
500nM 328.758 350.347 337.529 338.878 
1000nM 1042.816 968.462 1061.706 1004.328 
Table 3. Triplicate of luciferase activity data obtained from the experiment “RSG-1 
Responsiveness in 293T Cells”. Average of the three values were graphed in Figure 15.  	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